Market revenue in 2023 | USD 0.1 million |
Market revenue in 2030 | USD 1.3 million |
Growth rate | 45.6% (CAGR from 2023 to 2030) |
Largest segment | C.difficle |
Fastest growing segment | C.difficle |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C.difficle, Crohns disease, IBS, Diabetes |
Key market players worldwide | Carbios SA, Boise Cascade Co, Assembly Biosciences Inc, Wacker Chemie AG, SGS AG, Lonza Group Ltd, Arranta Bio, 4D Pharma, NIZO, Inpac Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to live biotherapeutic products and microbiome cdmo market will help companies and investors design strategic landscapes.
C.difficle was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Mexico live biotherapeutic products and microbiome cdmo market based on c.difficle, crohns disease, ibs, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is considered one of the most lucrative markets for R&D activities owing to the presence of skilled professionals, an increasing number of clinical research centers, and proximity to the U.S. The country provides a favorable environment to attract R&D investments, thereby boosting the demand for CDMOs. In addition, the availability of a diverse patient pool is one of the major drivers of the market.
The government also promotes R&D, which is expected to contribute to live biotherapeutic products and microbiome CDMO market growth. The country has witnessed a significant rise in investment from several companies, with local and foreign investors actively participating in the market due to the developing economy.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico live biotherapeutic products and microbiome cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Mexico live biotherapeutic products and microbiome cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account